How Trials and Targeted Therapies Are Reshaping Prostate Cancer Care

A regional roundtable discussion, moderated by Gregg Franklin, MD, PhD, New Mexico Cancer Center, explored current and emerging strategies in the management of metastatic castration-sensitive and castration-resistant prostate cancer, including clinical trial data, treatment sequencing, toxicity management, and the future role of targeted therapies and radiopharmaceuticals in patient care. Dr. Franklin was joined by other practitioners in the greater Albuquerque area, including Kathryn Chan, MD, Nexus Health; Laura Onorato, PA, New Mexico Cancer Center; Jose Avitia, MD, New Mexico Cancer Center; and Scott Herbert, MD, Nexus Health. In the final segment, the panel concludes with a discussion of emerging therapies and the future of metastatic prostate cancer. They highlight the evolving role of PARP inhibitors, the importance of germline and tissue profiling, and the potential of targeted treatments and radiopharmaceuticals, while expressing optimism that innovations in trials and sequencing will significantly improve patient outcomes over the next five to ten years.